Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy

Hematology Journal

Volumn 5, Issue 2, 2004, Pages 186-187

  Scaramucci, Laura ^a   Niscola, Pasquale ^a   Buffolino, Sonia ^b   Bongarzoni, Velia ^a   Cimino, Giuseppe ^b   Montanaro, Marco ^a  

^a Montefiascone Hospital Hematology   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CYTARABINE; DEXAMETHASONE; FLUDARABINE; MITOXANTRONE; RITUXIMAB;

ADULT; ANEMIA; BLOOD TOXICITY; CANCER GROWTH; CANCER STAGING; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; IMMUNOPHENOTYPING; LETTER; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; MITOXANTRONE; TREATMENT FAILURE; VIDARABINE;

EID: 1942441691     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200361     Document Type: Letter

References (9)

1. Mauro FR, Foa R, Meloni G, Gentile M, Giammartini E, Giannarelli D, De Propris MS et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica 2002: 87: 926-933.
2. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755-1762.
3. Itala M, Geisler CH, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002; 69: 129-134.
4. Keating MJ, O'Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 2002; 29 (1 Suppl 2): 70-74.
5. Schutz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU et al. A. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-3120.
6. Cheson BD, Bennet JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
7. Hainsworth JD, Litchy S, Burris III HA, Scullin Jr DC, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-4267.
8. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003; 21: 1746-1751.
9. Keating MJ, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.